What caused RNAC's earnings to miss forecasts in Q4 2023?

Cartesian Therapeutics Inc. (RNAC) did not miss earnings forecasts in Q4 2023. In fact, the company's financial performance for 2024 exceeded expectations in several key metrics. Here are the details that highlight the company's robust financial performance: 1. **Revenue Growth**: Cartesian Therapeutics reported a total revenue of $38.9 million for the year 2024, marking a significant increase of 50% compared to the previous year. This growth was primarily driven by an increase in collaboration and license revenue. 2. **Reduced Operating Loss**: The company's operating loss decreased by 49% from the previous year, amounting to $43.9 million. This reduction was primarily due to a decrease in operating expenses. 3. **Net Loss Improvement**: The net loss for the year ended December 31, 2024, was $77.4 million, which represented a substantial decrease of 65% compared to the net loss of $219.7 million in the previous year. The net loss per share improved from $49.76 in 2023 to $4.48 in 2024. 4. **EPS Beat Expectations**: The company's earnings per share (EPS) exceeded analyst estimates by 24%. This indicates that the company's performance for 2024 was better than what the market had anticipated. 5. **Strong Cash Position**: Cartesian Therapeutics maintained a strong financial position with $214.3 million in cash and equivalents, expected to fund operations into mid-2027. This financial strength underscores the company's ability to manage its finances effectively. In conclusion, Cartesian Therapeutics Inc. did not miss earnings forecasts in Q4 2023. Instead, the company's financial performance for 2024 was robust, with significant revenue growth, reduced operating losses, and improved net profitability. The company's EPS also beat expectations, reflecting strong financial performance and operational efficiency.